Search results
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 5 days agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 5 days agoPfizer said its treatment also didn’t hit any secondary endpoints. Dan Levy, development head for...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 6 days agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy ...
10 Shows Like 'Modern Family' to Watch Now
People Magazine· 3 days agoModern Family premiered in 2009 and quickly became a massive hit. The show was praised for its smart, often laugh-out-loud humor that helped complement...
‘Survivor’ Alum Parvati Shallow and Comedian Mae Martin ‘Have Never Been Happier,’ Dismiss Breakup...
AOL· 1 day agoSurvivor alum Parvati Shallow and comedian Mae Martin are still going strong. Martin, 37, shut down speculation that they and Shallow, 41, had broken up on Sunday, June 16, after the pair took ...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 5 days agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
UPDATE: Pfizer's phase 3 gene therapy trial fails to improve function for boys with Duchenne...
FierceBiotech· 6 days agoPfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 5 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said late Wednesday that ...